Filing Details
Vivos Therapeutics, Inc. (NASDAQ:VVOS) filed a Form 8-K with the Securities and Exchange Commission on July 07, 2026, disclosing a material event.
8k filedNASDAQ:VVOS
Vivos Therapeutics, Inc. (VVOS) Reports Material Event to SEC
Filing Details Vivos Therapeutics, Inc. (NASDAQ:VVOS) filed a Form 8-K with the Securities and Exchange Commission on July 07, 2026, disclosing a material event. Market Context…
Market Context
Vivos Therapeutics, Inc.'s stock currently trades at $0.48 with a market capitalization of $12.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Vivos Therapeutics, Inc.'s stock.
All SEC filings for Vivos Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View VVOS Stock Page
Frequently Asked Questions
Where can I read VVOS's SEC filings?
Browse all filings on our VVOS SEC filings page.
What types of SEC filings does Vivos Therapeutics, Inc. file?
Public companies like Vivos Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.